BioMarin Pharmaceutical Inc. (BMV:BMRN)

Mexico flag Mexico · Delayed Price · Currency is MXN
980.00
-9.00 (-0.91%)
At close: Nov 18, 2025
-42.35%
Market Cap 186.65B
Revenue (ttm) 56.75B
Net Income (ttm) 9.55B
Shares Out n/a
EPS (ttm) 49.17
PE Ratio 19.55
Forward PE 11.15
Dividend n/a
Ex-Dividend Date n/a
Volume 150
Average Volume 115
Open 980.00
Previous Close 989.00
Day's Range 980.00 - 980.00
52-Week Range 980.00 - 1,480.00
Beta n/a
RSI 32.38
Earnings Date Feb 20, 2026

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 3,040
Stock Exchange Mexican Stock Exchange
Ticker Symbol BMRN
Full Company Profile

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD Financial Statements

News

There is no news available yet.